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Biphasic dissolution method for quality control and assurance of 
drugs containing active substances in the form of weak acid salts
Substances in the form of weak acid salts have been found 
to be problematic for dissolution testing. Their absorption 
can start only aft er they are turned into the form of an acid 
following the gastric passage although they were adminis-
tered in the form of a salt. Due to poor solubility, they can-
not be tested in acidic gastric environment for a biased dis-
solution profi le. The biphasic dissolution method is 
promising for overcoming this obstacle. Tablets with war-
farin clathrate sodium salt in two concentrations and two 
diﬀ erent particle size distributions were tested as a suitable 
model for fi nding the medium and process conditions of 
dissolution. The dissolution method based on the use of the 
upper organic layer (1-octanol) and the lower aqueous layer 
(0.1 mol L–1 HCl) was found suitable and discriminatory for 
tablets containing active substances in the form of salts of 
weak acids. The method also refl ects physical diﬀ erences in 
the quality of used substances.
Keywords: weak acid salts, warfarin sodium, dissolution 
method
Dissolution methods for oral drugs containing an active substance in the form of a 
weak acid salt have to refl ect their specifi c physicochemical and biological properties. In 
acidic gastric environment, these substance turn into the acid form, which is oft en poorly 
soluble. Therefore, dissolution testing in simulated gastric fl uid is out of the question. The 
warfarin sodium tablets USP monograph (warfarin is a typical example of the above men-
tioned drugs) requires only water as a dissolution medium (1). This method, which is 
neither biorelevant nor discriminatory because of very good solubility of warfarin sodium 
in water, contains only one sampling point. This does not allow adequate evaluation of any 
changes in the quality of the active substance or the impact of diﬀ erent active substance 
concentrations in tablets of diﬀ erent strengths on the dissolution profi le. However, a suit-
able discriminatory dissolution method can unveil diﬀ erences in the active substance lib-
eration with respect to its quality and concentration under conditions close to those present 
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Biphasic dissolution is a suitable dissolution method for drugs in the form of weak acid 
salts, combining the acidic gastric environment and lipophilic character of cell membranes 
through which the drug is absorbed. Having partially dissolved in the aqueous acidic 
phase, the active substance in the form of a weak acid may move by diﬀ usion to the or-
ganic layer; fi nally, a balanced state dependent on the partition coeﬃ  cient is achieved. Bi-
phasic dissolution system is simple, easy to implement and uses commonly available 
equipment. The advantage of this system lies in its single-step likeness to in vivo liberation, 
dissolution and absorption of active substances in the gastrointestinal tract (3). A com-
mercial automated equipment for biphasic dissolution testing has been recently intro-
duced, allowing easy, routine use of this method (4). The aim of this study was to identify 
suitable conditions for testing substances in the form of weak acid salts, using a model 
example of tablets containing warfarin sodium in two concentrations and two particle size 
distributions. The resulting dissolution profi le should be similar as much as possible to the 
in vivo liberation. Furthermore, the proposed method was evaluated to fi nd if it is dis-




Warfarin standard, 1-octanol, methanol and hydrochloric acid were all obtained from 
Sigma Aldrich (UK). All materials were of analytical grade and used without further pu-
rifi cation. Deionized water was prepared in house. The composition of tested tablets and 
used raw material is given in Table I.
Table I. Composition of the blends and physical properties of individual constituents
Component Producer
Particle size (μm)a Content (%)
D10 D50 D90 W1A W10A W1B W10B
Warfarin 
sodium clathrate Pliva (Croatia)
0.9 4.8 10.3 2.0 –
2.7 22.5 234.3 – 2.0
Di-cafos 92-14 Budenheim KG (Germany) 2.4 152.3 309.8 70.0
Avicel PH 101 FMC BioPolymer (USA) 14.7 46.3 110.7 25.0




(Germany) 2.6 10.2 23.1 1.0
aDx – x is % of measured particles that are smaller than this size (μm).
Di-cafos – calcium hydrogen phosphate, Avicel PH 101 – microcrystalline cellulose, Ac-Di-Sol – sodium crosscar-
mellose
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Manufacturing of tablets
In order to design the biphasic dissolution method, tablets containing 1 mg or 10 mg 
of API were manufactured by direct compression from a single tablett ing blend. All man-
ufactured batches met the requirements of valid USP and EP monographs on friability, 
hardness and disintegration. Two batches of each strength were prepared, diﬀ ering in 
particle size distribution of API, i.e., batches with 1 or 10 mg of API of narrow particle size 
distribution (batches W1A and W10A), respectively, and of wide particle size distribution 
(batches W1B and W10B). The composition of tablett ing blends and the manufacturing 
process are based on the VFU patent (5) and literature (6).
The composition of the blends and some physicochemical properties of raw materials 
are listed in Table I. All constituents were sieved through a 250-μm sieve. All constituents 
without magnesium stearate were mixed for 10 minutes, then magnesium stearate was 
added and another 5 minutes of mixing followed. A Turbula (T2C, Switzerland) homoge-
nizer was used, speed 40 rpm. The mass of a batch was 500.0 g.
Tablets containing 1 mg of API weighed 54.2 mg. They were fl at with a 5-mm diameter 
and hardness about 100 N. Tablets containing 10 mg of API weighed 542.0 mg; they were 
fl at with a 10-mm diameter and hardness about 100 N. All batches were produced using 
an eccentric press (Korsch EK0, Germany).
Dissolution test
The tests were carried out on a SOTAX (AT 7 Donau Lab, Switzerland). Biphasic dis-
solution was performed using 900 mL of 0.1 mol L–1 HCl and 70.0 g of 1-octanol maintained 
at 37.0 ± 0.5 °C, using USP paddles at a rotation speed of 50 rpm. One mL of dissolution 
medium (water and organic phase) was withdrawn aft er 1, 2, 4 and 8 hours of dissolution. 
Dissolution of tablets in water was done according to the USP monograph using 900 mL of 
water maintained at 37 °C and paddles rotating at 50 rpm (1). Sampling points were at 10, 
20, 30 and 60 min. Samples from all dissolution tests were fi ltered using 0.45-μm syringe 
fi lters; warfarin content was then analyzed by liquid chromatography. For each sampling 
point, mean and standard deviations were calculated.
Chromatographic analysis
To measure warfarin content in samples, we used high performance liquid chroma-
tography and adhered to the published method (6). Quantifi cation followed the calibration 
curve, which expressed the relation between the peak area and warfarin concentration 
(samples from organic phase) or warfarin clathrate sodium salt concentration (samples 
from aqueous phase).
Statistical analysis
To compare the dissolution profi les of tablet batches, the diﬀ erence factor f1 and the 
similarity factor f2 were calculated. Diﬀ erence and similarity factors were determined for 
samples W1A–W10A, W1B–W10B to fi nd the infl uence of warfarin content in tablets (1 mg 
or 10 mg) and for samples W1A–W1B, W10A–W10B to examine the eﬀ ect of warfarin par-
ticle size distribution (mean particle size 4.8 or 22.5 μm).
142
A. Franc et al.: Biphasic dissolution method for quality control and assurance of drugs containing active substances in the form of 
weak acid salts, Acta Pharm. 66 (2016) 139–145.
 
RESULTS AND DISCUSSION
In this study, warfarin sodium was chosen as a model drug for the development of a 
biphasic dissolution method because of its physicochemical properties. Warfarin is used 
as sodium salt and as free acid; it is acidic (pKa = 5.0) and poorly soluble in water. In order 
to develop a discriminatory dissolution method suitable for evaluation of active substanc-
es (weak acids), tablets containing warfarin clathrate sodium salt were prepared (composi-
tion in Table I) choosing strengths of commercially available warfarin (1 mg and 10 mg). 
Considering the fact that physical properties of API have an impact on warfarin pharma-
cokinetics (7), diﬀ erent particle size distribution of the active substance was chosen as a 
qualitative parameter (D50 = 4.8 or 22.5 μm). These two variables were chosen because the 
optimal dissolution method should identify changes in product quality while being suit-
able for the whole range of marketed strengths. Manufactured tablets were tested accord-
ing to EP and USP quality requirements for friability, hardness and disintegration. The 
results of they were similar, and as these tests were run according to pharmacopoeial 
monographs, they prove that physical parameters will not have a signifi cant impact on the 
diﬀ erences in dissolution profi les. The USP dissolution method was used to evaluate tab-
lets with diﬀ erent warfarin contents and particle size distribution. Fig. 1 shows that aft er 
10 minutes, almost all active substance was liberated in all batches and no diﬀ erences be-
tween samples could be observed. This method is neither discriminatory nor biorelevant.
The conditions of a dissolution method suitable for dosage forms containing active 
substances in the form of salts of weak acids should simulate real conditions in the gastro-
intestinal tract as much as possible. Therefore, we chose 0.1 mol L–1 hydrochloric acid for 
the aqueous phase (simulation of gastric environment) and 1-octanol for the organic phase 
(simulation of transport through the biological barrier). Further dissolution conditions 
Fig. 1. Dissolution profi les of warfarin tablets under different conditions (USP method and biphasic method): 
(□) W10A, (○) W1A, () W10B, () W1B (mean ± SD; n = 6).
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such as the volume of aqueous phase, temperature and paddle rotations follow dissolution 
requirements as given in the Warfarin Sodium Tablets USP monograph (1). As small as 
possible volume of organic phase was chosen to allow easy sampling and meeting „sink 
conditions“ (the concentration of saturated solution of warfarin in 1-octanol is fi ve times 
higher than the concentration of warfarin solution in 1-octanol obtained by dissolving 
completely the dose contained in one tablet) during the dissolution process of both tested 
strengths.
At fi rst sight, the dissolution profi les obtained by biphasic and pharmacopoeial meth-
ods (Fig. 1) state clearly that dissolution profi les in the 1-octanol phase do diﬀ er whereas 
those acquired by the USP dissolution method do not. Using the similarity factor f2 and the 
diﬀ erence factor f1 for statistical evaluation of the likeness of these profi les (Table II), we 
found out that the dissolution profi les of tablets with diﬀ erent strengths diﬀ er statistically 
signifi cantly only in the case of API with wide particle size distribution. Dissolution pro-
fi les of tablets with diﬀ erent strengths and API with narrow particle size distribution are 
statistically diﬀ erent when using f1 for comparison ( f1 > 15.0). When using f2, there was no 
statistically signifi cant diﬀ erence between these profi les; however, f2 was close to the crit-
ical value of 50. Under chosen conditions of biphasic dissolution, the method is discrimina-
tory with respect to the content of active substance in the tablet. Statistical comparison of 
the dissolution profi les of tablets with the same strength and diﬀ erent particle size distri-
bution of API has proven that these dissolution profi les are similar (according to both f2 
and f1). Nevertheless, the actual values of f2 and f1 show that the impact of particle size 
distribution on the dissolution profi le is higher in tablets with higher API content ( f2 = 54.5, 
f1 = 11.7) than in tablets with lower content of API ( f2 = 76.7, f1 = 4.3). Diﬀ erent contents of 
API in tablets led to more pronounced diﬀ erences in dissolution profi les than physical 
properties, i.e., particle size distribution of the active substance.
In the course of biphasic dissolution testing, the concentration of API in the aqueous 
phase (0.1 mol L–1 HCl) was measured as well. In all batches, the content of API in the aque-
ous phase was lower than 15 % (Fig. 1). During the dissolution test, the non-ionized active 
substance is moving continually to the lipophilic phase, similarly to the process of absorp-
tion in the gastrointestinal tract. This fi nding is in accord with the requirements of a bio-
relevant dissolution method.
The described biphasic dissolution method meets the requirements for the calculation 
and use of f2 and f1 factors with respect to the number of sampling points (60, 120, 240 and 
480 minutes), RSD values (lower than 20 % at the fi rst point, lower than 10 % at subsequent 
points, Table III), and only one point lies outside the line of 85 % of dissolved active sub-
stance. Owing to the character of the dissolution method, which takes into account physi-
Table II. Biphasic dissolution method: diﬀ erence factor and similarity factor
Sample Reference f2 f1
W10A W1A 52.8 16.5
W10B W1B 40.9 29.3
W10A W10B 54.5 11.7
W1A W1B 76.7 4.3
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ological conditions, this method meets general requirements for the design of dissolution 
methods. This method can be considered biorelevant, since 50 % of active substance is 
released in 120–240 minutes, corresponding to the peak concentration of warfarin in blood 
plasma in vivo, i.e., 108–222 min aft er oral administration (7). The method seems to be suit-
able for IVIVC (8).
CONCLUSIONS
A biphasic discriminatory dissolution method was designed based on using the up-
per organic layer (1-octanol) and the lower aqueous layer (0.1 mol L–1 HCl), which simulates 
the gastric environment. The method seems to be suitable for dosage forms containing 
active substances in the form of salts of weak acids, where dissolution testing in simulated 
gastric fl uid is inconvenient. The designed conditions of biphasic dissolution testing are 
suﬃ  cient to meet the requirements for f1 and f2 calculation. The method is suitable for 
statistical comparison of the dissolution profi les of tablets with diﬀ erent quantitative or 
qualitative parameters and method for the development, clinical evaluation, as well as 
routine quality control release evaluation. As the equipment for routine biphasic dissolu-
tion measurement is already available, this method could play a major role in quality as-
surance and control as well as help decrease development costs for both innovative and 
generic pharmaceutical industry.
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